Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials
…, C Chauhan, NK Aaronson, C Coens… - JNCI: Journal of the …, 2014 - academic.oup.com
Abstract Background The National Cancer Institute's Symptom Management and Health-
Related Quality of Life Steering Committee held a clinical trials planning meeting …
Related Quality of Life Steering Committee held a clinical trials planning meeting …
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the …
Summary Patient-reported outcomes (PROs), such as symptoms, function, and other health-
related quality-of-life aspects, are increasingly evaluated in cancer randomised controlled …
related quality-of-life aspects, are increasingly evaluated in cancer randomised controlled …
Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards
…, MJB Taphoorn, G Velikova, C Coens - The Lancet …, 2016 - thelancet.com
Measures of health-related quality of life (HRQOL) and other patient-reported outcomes
generate important data in cancer randomised trials to assist in assessing the risks and …
generate important data in cancer randomised trials to assist in assessing the risks and …
[HTML][HTML] Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
…, A Casado, C Mendiola, C Coens… - … England Journal of …, 2010 - Mass Medical Soc
Background Primary debulking surgery before initiation of chemotherapy has been the
standard of care for patients with advanced ovarian cancer. Methods We randomly assigned …
standard of care for patients with advanced ovarian cancer. Methods We randomly assigned …
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 …
…, P Petignat, DAX Schinagl, C Coens… - The lancet …, 2014 - thelancet.com
Background If treatment of the axilla is indicated in patients with breast cancer who have a
positive sentinel node, axillary lymph node dissection is the present standard. Although …
positive sentinel node, axillary lymph node dissection is the present standard. Although …
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
…, M Ouali, S Marreaud, R Hodge, MR Dewji, C Coens… - The Lancet, 2012 - thelancet.com
Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in
patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of …
patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of …
[HTML][HTML] Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
…, GC Jayson, G Kristensen, C Mediola, C Coens… - The Lancet, 2010 - thelancet.com
Background Serum CA125 concentration often rises several months before clinical or
symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 …
symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 …
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant …
…, L Giurgea, P Timmers, C Coens… - Journal of the …, 2003 - academic.oup.com
Background: All randomized trials of adjuvant chemotherapy for early-stage ovarian cancer
have lacked the statistical power to show a difference in the effect on survival between …
have lacked the statistical power to show a difference in the effect on survival between …
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials
C Quinten, C Coens, M Mauer, S Comte… - The lancet …, 2009 - thelancet.com
Background Although individual studies show that baseline health-related quality of life
(HRQOL) is a prognostic factor for survival, contradictory results have been published and …
(HRQOL) is a prognostic factor for survival, contradictory results have been published and …
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for …
…, S Tateo, M Franchi, JJ Jobsen, C Coens… - European Journal of …, 2008 - Elsevier
The management of uterine sarcomas continues to present many difficulties. Primary
surgery is the optimal treatment but the role of post-operative radiation remains uncertain. In …
surgery is the optimal treatment but the role of post-operative radiation remains uncertain. In …